[Current pathophysiological and clinical aspects of the mode of action of blood glucose lowering sulfonamides].
D000367:Age Factors; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002417:Cattle; D003920:Diabetes Mellitus / Q000503:physiopathology; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism; D005951:Glucose Tolerance Test; D006651:Histocytochemistry; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism / Q000652:urine; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000502:physiology; D009765:Obesity; D010179:Pancreas / Q000187:drug effects; D010477:Perfusion; D013449:Sulfonamides / Q000494:pharmacology*; D013997:Time Factors; D014044:Tolbutamide / Q000494:pharmacology
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D013449:Sulfonamides; D014044:Tolbutamide; D005947:Glucose